• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Upstream Bio Inc.

    2/14/25 4:23:29 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Upstream Bio, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    91678A107

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    91678A107


    1Names of Reporting Persons

    TCG Crossover GP I, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,801,763.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,801,763.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,801,763.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  These securities are held of record by TCG Crossover I (as defined in item 2(a) below). TCG Crossover GP I (as defined in item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. The amount beneficially owned by each Reporting Person is determined based on 53,596,601 shares of Common Stock outstanding as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission (the SEC) on November 7, 2024 (the Form 10-Q).


    SCHEDULE 13G

    CUSIP No.
    91678A107


    1Names of Reporting Persons

    TCG Crossover Fund I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,801,763.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,801,763.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,801,763.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  These securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. The amount beneficially owned by each Reporting Person is determined based on 53,596,601 shares of Common Stock outstanding as reported in the Issuer's Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    91678A107


    1Names of Reporting Persons

    Chen Yu
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,801,763.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,801,763.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,801,763.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  These securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. The amount beneficially owned by each Reporting Person is determined based on 53,596,601 shares of Common Stock outstanding as reported in the Issuer's Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Upstream Bio, Inc.
    (b)Address of issuer's principal executive offices:

    890 Winter Street, Suite 200, Waltham, MA 02451
    Item 2. 
    (a)Name of person filing:

    This joint statement on Schedule 13G is being filed by TCG Crossover Fund I, L.P. (TCG Crossover I), TCG Crossover GP I, LLC (TCG Crossover GP I and together with TCG Crossover I, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 99.1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.
    (c)Citizenship:

    TCG Crossover GP I is a limited liability company organized under the laws of the State of Delaware. TCG Crossover I is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    91678A107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding comments.
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding comments.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person and the corresponding comments.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person and the corresponding comments.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person and the corresponding comments.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person and the corresponding comments.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Under certain circumstances set forth in the limited partnership agreements of TCG Crossover I and the limited liability company agreement of TCG Crossover GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TCG Crossover GP I, LLC
     
    Signature:/s/ Craig Skaling
    Name/Title:Authorized Signatory
    Date:02/14/2025
     
    TCG Crossover Fund I, L.P.
     
    Signature:/s/ Craig Skaling
    Name/Title:Authorized Signatory
    Date:02/14/2025
     
    Chen Yu
     
    Signature:/s/ Craig Skaling
    Name/Title:By POA as Attorney-in-Fact
    Date:02/14/2025
    Get the next $UPB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPB

    DatePrice TargetRatingAnalyst
    11/5/2024$75.00Overweight
    Piper Sandler
    11/5/2024$38.00Overweight
    JP Morgan
    11/5/2024Outperform
    William Blair
    11/5/2024Buy
    TD Cowen
    More analyst ratings

    $UPB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Upstream Bio Appoints Stacy Price as Chief Technology Officer

      WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

      5/20/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

      – Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended Mar

      5/6/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      – Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a summary of recent business highlights. Upstream is developing verekitug, the only monoclonal

      3/12/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Upstream Bio with a new price target

      Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

      11/5/24 6:29:20 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Upstream Bio with a new price target

      JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

      11/5/24 6:28:28 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Upstream Bio

      William Blair initiated coverage of Upstream Bio with a rating of Outperform

      11/5/24 6:28:02 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      11/7/24 9:24:55 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Upstream Bio Inc.

      SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

      10/22/24 4:06:27 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      10/18/24 6:10:56 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Leadership Updates

    Live Leadership Updates

    See more
    • Upstream Bio Appoints Stacy Price as Chief Technology Officer

      WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

      5/20/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Appoints Allison Ambrose as General Counsel

      WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

      12/17/24 8:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chimovits Erez bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:19:30 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:17:52 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ai Upstream Llc bought $19,975,000 worth of shares (1,175,000 units at $17.00) and converted options into 4,319,410 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:05:04 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Upstream Bio Inc.

      10-Q - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:10:23 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:05:10 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Upstream Bio Inc.

      DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)

      4/17/25 4:10:03 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Sutherland Everett Rand

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:32:21 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO and COO Gray Michael

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:31:01 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Houghton Adam

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:29:56 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care